Magazine
ENEWS
SUBSCRIBE
WEBINARS
PODCASTS
EBOOKS
Edit submissions
Press releases
Media kit
Innovation Awards
May 9, 2024
Pfizer halts part of DMD trial following patient death | Catalent, Siren ink gene therapy manufacturing partnership
May 8, 2024
FTC extends review of Novo-Catalent deal | Vertex advances pipeline with NDA submission for cystic fibrosis
May 7, 2024
AstraZeneca completes gene editing investment pact with Cellectis | GlycoMimetics AML drug misses in phase 3 trial
May 4, 2024
Novartis to buy radiopharma company Mariana | FDA grants Amolyt hypoparathyroidism drug Fast Track designation
May 3, 2024
Emergent to axe employees, close plants | Moderna abandons Metagenomi gene editing deal
May 2, 2024
Neurocrine wins FDA nod for 'sprinkle' Ingrezza formulation | FDA to host listening session for AdComm improvements
May 1, 2024
Pfizer-Genmab ADC wins full approval in cervical cancer | Novartis, PeptiDream expand peptide discovery pact
Apr 30, 2024
X4 Pharma wins FDA nod to treat rare immunodeficiency disease | Addex, Janssen epilepsy drug falls short in phase 2 trial
Apr 27, 2024
FDA approves Pfizer hemophilia B gene therapy | Merck KGaA builds biopharma research center
Apr 26, 2024
BMS unveils cost-saving initiative, layoffs | Regeneron, Mammoth ink gene editing collaboration
Apr 25, 2024
Xaira Therapeutics launches AI drug discovery mission backed by $1B in funding | Novartis wins rare cancer pediatric indication for Lutathera
Apr 24, 2024
Eli Lilly to buy Nexus injectables manufacturing site | Incyte snaps up Escient, boosting neurosensory-inflammatory pipeline
Apr 23, 2024
Ipsen, Skyhawk ink $1.8B neurological RNA modulator deal | BMS, Cellares sign CAR-T supply deal
Apr 20, 2024
Roche lung cancer blockbuster wins approval in early-stage NSCLC | FDA accepts Vertex non-opioid pain med NDA
Apr 19, 2024
Cerevel Parkinson’s drug gets phase 3 win ahead of AbbVie deal | Takeda inks immuno-oncology partnership with Kumquat
Apr 18, 2024
Eli Lilly weight loss drug significantly improves sleep apnea symptoms | GSK antibiotic hits phase 3 goals in gonorrhea
Apr 17, 2024
Novartis Factor B inhibitor grabs priority review in IgAN | Genentech cancer drug shows promise in earlier DLBCL treatment
Apr 16, 2024
EMA finds no link between GLP-1 drugs and suicidal thoughts | Genentech ends $3B Adaptimmune T-cell collab
Apr 13, 2024
Fujifilm to spend $1.2B on North Carolina CDMO expansion | Florida judge dismisses Eli Lilly compounding suit
Apr 12, 2024
Vertex to buy Alpine for $4.9B | Novartis to license Arvinas protein degrader
Apr 11, 2024
Novartis reveals development layoffs | Ginkgo Bioworks, Novo Nordisk expand partnership
Apr 10, 2024
BrainStorm, FDA align on ALS trial design | Merck acquires ADC safety startup Abceutics
Apr 9, 2024
AstraZeneca, Daiichi snag another FDA approval for cancer ADC | BMS schizophrenia drug improves symptoms in phase 3 trial
Apr 6, 2024
J&J boosts medtech biz with $13.1B Shockwave deal | Merck KGaA, Caris enter $1.4B ADC deal
Apr 5, 2024
Amylyx to withdraw ALS drug from market | Basilea wins hard-fought FDA nod for antibiotic
Latest Edition